Aspirin's anti-cancer benefits greater than previously thought

Three studies in prestigious medical journals, including two in The Lancet and one in The Lancet Oncology offer the best evidence yet of the thrilling anti-cancer and cancer preventive effects of aspirin in an older population.

For people in middle age, a low daily dose of aspirin can help prevent the development of cancer, especially if they are at higher risk of cancer than the rest of the population. Unlike prior beliefs, which suggested that this benefit did not begin for ten years after beginning taking it, this new research suggests that the benefits may begin after just a couple of years.

Finally, researchers believe they have evidence that aspirin can even treat cancer in people who already have it, adding to the growing body of evidence that aspirin may have some anti-metastatic properties.

This does not mean researchers are advocating aspirin as an anti-cancer medication just yet; they would like future research to address the following issues:

-- What is the optimal period of time to be taking aspirin for?
-- At what age does the biggest benefit and smallest risk occur?
-- Who is most likely to benefit, and who is most likely to get side effects?
-- How can we minimize the risk of a stroke when people stop taking the drug?

Source: Medical News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap